AHA Coding Clinic® for HCPCS - 2013 Quarter 3; Ask the Editor
Zoledronic acid (Reclast®)
The coders at our facility are concerned about the correct reporting of Zoledronic acid (Reclast ® ). This drug is packaged in a bottle/vial for intravenous infusion. One bottle/vial contains 5 mg of the Zoledronic acid solution. A normal dose of Zoledronic acid is 5 mg, which should only be administered once every 12 months. The dilemma is that according to the Centers for Medicare & Medicaid Services (CMS) drugs should not be reported based on how the drug is packaged, stored, or stocked. So, if a patient receives 5 mg of Zoledronic acid, how would this be correctly reported when the HCPCS code descriptor states Q2051 , Injection, zoledronic acid, not otherwise specified, 1 mg? ...
Subscribe or sign in to view the full article.
Article Overview
This article addresses a facility coding question about reporting zoledronic acid (Reclast®) in the outpatient setting. It focuses on how the drug is presented and reported under CMS and OPPS guidance, and it is relevant to hospital outpatient coders, billing staff, and reimbursement professionals who handle drug administration claims and HCPCS reporting.
Why This Topic Matters
Accurate drug reporting affects outpatient claim submission and payment integrity. The article helps readers understand how to approach reporting for a commonly used bisphosphonate within CMS-aligned facility billing processes.
What You Will Learn
- How the article frames a facility reporting question about zoledronic acid
- How the discussion relates CMS packaging guidance to outpatient drug reporting
- How HCPCS reporting is addressed in the outpatient prospective payment system context
- What type of billing scenario the article is concerned with
Who Should Read This
- Hospital outpatient coders
- Facility billing staff
- Reimbursement specialists
- Charge capture teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com